ReviewJournal of inflammation (London, England)2026
Bromodomain-containing protein 4 in inflammatory diseases: molecular mechanisms and therapeutic potential.
Review in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bromodomain-containing protein 4 (BRD4), a key member of the bromodomain and extra-terminal (BET) family, plays a critical role in regulating gene expression as an epigenetic reader. While its canonical role involves transcriptional control, BRD4 also acts as a dynamic integrator of intracellular signaling pathways and chromatin architecture, linking environmental and inflammatory stimuli to lasting gene expression changes. Recent research highlights BRD4 as a central regulator in inflammatory transcriptional networks, contributing to chronic inflammation in autoimmune diseases, cardiovascular conditions, metabolic disorders, and cancer-related inflammation. BRD4 interacts with major inflammatory transcription factors, such as NF-κB, STATs, and AP-1, amplifying transcriptional responses and maintaining an open chromatin state at super-enhancers that control inflammatory gene clusters. This has prompted interest in pharmacological strategies targeting BET proteins, with promising anti-inflammatory and antifibrotic effects in preclinical models. This review consolidates current knowledge on BRD4’s molecular mechanisms in inflammation and evaluates the potential of BET inhibitors as therapeutic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.